[go: up one dir, main page]

MA32975B1 - Antagonistes de c5ar - Google Patents

Antagonistes de c5ar

Info

Publication number
MA32975B1
MA32975B1 MA34025A MA34025A MA32975B1 MA 32975 B1 MA32975 B1 MA 32975B1 MA 34025 A MA34025 A MA 34025A MA 34025 A MA34025 A MA 34025A MA 32975 B1 MA32975 B1 MA 32975B1
Authority
MA
Morocco
Prior art keywords
c5ar
antagonists
compounds
relates
receptors
Prior art date
Application number
MA34025A
Other languages
Arabic (ar)
English (en)
Inventor
Pingchen Fan
Kevin Lloyd Greenman
Manmohan Reddy Leleti
Yandong Li
Jay Powers
Hiroko Tanaka
Ju Yang
Yibin Zeng
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42267017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32975(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA32975B1 publication Critical patent/MA32975B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)

Abstract

L'invention porte sur des composés qui sont des modulateurs du récepteur de C5a. Les composés sont des pipéridines substituées, et sont utiles dans des compositions pharmaceutiques. L'invention porte également sur des méthodes de traitement de maladies et de troubles mettant en jeu l'activation pathologique de récepteurs de C5a.
MA34025A 2008-12-22 2009-12-21 Antagonistes de c5ar MA32975B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13991908P 2008-12-22 2008-12-22
PCT/US2009/068941 WO2010075257A1 (fr) 2008-12-22 2009-12-21 Antagonistes de c5ar

Publications (1)

Publication Number Publication Date
MA32975B1 true MA32975B1 (fr) 2012-01-02

Family

ID=42267017

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34025A MA32975B1 (fr) 2008-12-22 2009-12-21 Antagonistes de c5ar

Country Status (36)

Country Link
US (6) US8445515B2 (fr)
EP (4) EP3508477B1 (fr)
JP (1) JP5819730B2 (fr)
KR (1) KR101680818B1 (fr)
CN (1) CN102264227B (fr)
AR (1) AR077162A1 (fr)
AU (1) AU2009330194B2 (fr)
BR (1) BRPI0923384B1 (fr)
CA (2) CA2965223C (fr)
CO (1) CO6400172A2 (fr)
CY (1) CY1125130T1 (fr)
DK (2) DK3078658T3 (fr)
EA (1) EA020874B1 (fr)
ES (2) ES2734746T3 (fr)
FR (1) FR22C1020I2 (fr)
HK (1) HK1164639A1 (fr)
HR (1) HRP20161010T1 (fr)
HU (2) HUE030630T2 (fr)
IL (1) IL213676A (fr)
JO (1) JO3346B1 (fr)
LT (2) LT3508477T (fr)
MA (1) MA32975B1 (fr)
MX (1) MX2011006550A (fr)
NL (1) NL301166I2 (fr)
NO (1) NO2022018I1 (fr)
NZ (1) NZ594140A (fr)
PL (1) PL2381778T3 (fr)
PT (2) PT3078658T (fr)
RS (1) RS54998B1 (fr)
SG (1) SG172338A1 (fr)
SI (1) SI2381778T1 (fr)
SM (1) SMT202200074T1 (fr)
TW (1) TWI465434B (fr)
UA (1) UA112514C2 (fr)
WO (1) WO2010075257A1 (fr)
ZA (1) ZA201104588B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
EP3508477B1 (fr) 2008-12-22 2021-11-10 ChemoCentryx, Inc. Antagonistes du c5ar
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
BR112013031198B1 (pt) 2011-06-06 2020-10-20 Novo Nordisk A/S anticorpo de ligação a c5ar e seu uso
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
AU2013255470B2 (en) * 2012-05-04 2015-09-17 Novartis Ag Complement pathway modulators and uses thereof
DE102012109101A1 (de) 2012-09-26 2014-03-27 Endress + Hauser Gmbh + Co. Kg Füllstandsmessgerät
MX368492B (es) 2014-09-29 2019-10-04 Chemocentryx Inc Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.
JP7339733B2 (ja) 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法
MX2018011831A (es) 2016-04-04 2019-02-13 Chemocentryx Inc Antagonistas solubles de receptor de c5aa(c5ar).
JP7486415B2 (ja) 2017-04-03 2024-05-17 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
KR102638253B1 (ko) 2017-05-31 2024-02-16 케모센트릭스, 인크. C5a 억제제로서의 6-5 융합 고리
KR102586710B1 (ko) 2017-05-31 2023-10-10 케모센트릭스, 인크. C5a 억제제로서의 5-5 융합 고리
JP7502865B2 (ja) * 2017-06-23 2024-06-19 インフラルクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｃ５ａ活性のインヒビターでの炎症性疾患の処置
CN119280233A (zh) 2017-07-31 2025-01-10 诺华股份有限公司 玛沃谷兰在减少可卡因使用或预防复用可卡因中的用途
JP2021501175A (ja) 2017-10-30 2021-01-14 ケモセントリックス，インコーポレイティド 免疫調節剤としての重水素化化合物
EP3728202A4 (fr) 2017-12-22 2021-05-26 ChemoCentryx, Inc. Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
US10828285B2 (en) 2017-12-22 2020-11-10 Chemocentryx, Inc. Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
SG11202009588PA (en) 2018-04-02 2020-10-29 Chemocentryx Inc PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS
CN108727354A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108727355A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108440514A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108440513A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108558844A (zh) * 2018-05-16 2018-09-21 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
KR20210018906A (ko) 2018-06-07 2021-02-18 케모센트릭스, 인크. Anca 연관 혈관염에 대한 c5a 길항제의 투여 및 효과
MX2021006242A (es) 2018-11-30 2021-09-10 Chemocentryx Inc Formulaciones de capsula.
US11149009B2 (en) * 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
JP2022539830A (ja) 2019-07-10 2022-09-13 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１阻害剤としてのインダン
JP2022551973A (ja) 2019-10-16 2022-12-14 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１疾患の処置のためのヘテロアリール－ビフェニルアミド
CA3152714A1 (fr) 2019-10-16 2021-04-22 Pingchen Fan Heteroaryl-biphenylamines pour le traitement de maladies pd-l1
JP2022554019A (ja) * 2019-11-08 2022-12-27 ケモセントリックス，インコーポレイティド 補体成分Ｃ５ａ受容体の遊離塩基結晶形態
MX2022005406A (es) * 2019-11-08 2022-05-24 Chemocentryx Inc Forma amorfa de un receptor de componente c5a de complemento.
IL292371A (en) * 2019-11-08 2022-06-01 Chemocentryx Inc Salt forms of a complement component c5a receptor
KR20220159983A (ko) 2020-03-27 2022-12-05 인플라알엑스 게엠베하 코로나 바이러스 감염 치료를 위한 C5a의 억제제
MX2023001504A (es) * 2020-08-07 2023-04-27 Kira Pharmaceuticals Suzhou Ltd Compuestos como inhibidores del receptor del componente complemento 5a (c5ar).
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022078269A1 (fr) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Forme cristalline d'avacopan, son procédé de préparation et son utilisation
KR20230097099A (ko) 2020-10-28 2023-06-30 케모센트릭스, 인크. 화농성 한선염의 치료 방법
CN113957106B (zh) * 2021-11-03 2024-04-19 暨明医药科技（苏州）有限公司 一种Avacopan及其中间体的制备方法
CN114163380B (zh) * 2021-12-06 2023-11-07 重庆医科大学 阿伐可泮中间体及其制备方法和用途
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法
EP4479546A2 (fr) 2022-02-16 2024-12-25 Teva Pharmaceuticals International GmbH Processus de préparation d'avacopan et de ses intermédiaires
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
JPS5331669A (en) * 1976-09-06 1978-03-25 Kissei Pharmaceut Co Ltd Novel n-acylpiperidinecaroxyanilide derivatives and their preparation
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
EP1087937A1 (fr) * 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
KR20010082184A (ko) 1998-08-28 2001-08-29 추후제출 p38-α 키나제의 저해체
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
WO2001085720A1 (fr) 2000-05-05 2001-11-15 Smithkline Beecham Corporation Nouveaux anti-infectieux
ATE485266T1 (de) 2000-08-10 2010-11-15 Mitsubishi Tanabe Pharma Corp 3-substituierte harnstoffderivate und deren medizinische verwendung
KR100842791B1 (ko) 2000-09-14 2008-07-01 미쓰비시 타나베 파마 코퍼레이션 신규한 아미드 유도체 및 그의 의약적 용도
KR20030060887A (ko) 2000-09-29 2003-07-16 뉴로젠 코포레이션 고친화성 저분자 Ｃ5ａ 수용체 조절자
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
DE10293175D2 (de) 2001-07-19 2004-07-01 Luk Lamellen & Kupplungsbau System zum Ansteuern einer Komponente eines Getriebes eines Fahrzeuges unter Berücksichtigung eines Fluidverlustes
CN100391537C (zh) 2001-08-17 2008-06-04 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
EP1487798A4 (fr) 2002-03-28 2005-07-13 Neurogen Corp Tetrahydroisoquinoleines substituees servant de modulateurs du recepteur c5a
WO2003082826A1 (fr) 2002-03-28 2003-10-09 Neurogen Corporation Biarylamides substitues en tant que modulateurs du recepteur c5a
CA2480082A1 (fr) 2002-03-29 2003-10-16 Neurogen Corporation Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
EP1529046A1 (fr) 2002-08-08 2005-05-11 Boehringer Ingelheim Pharmaceuticals Inc. Composes benzimidazole substitues
WO2004018460A1 (fr) 2002-08-21 2004-03-04 Neurogen Corporation Aminomethyl imidazoles en tant que modulateurs de recepteurs c5a
US7455837B2 (en) 2002-11-05 2008-11-25 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2504941C (fr) 2002-11-08 2012-06-26 Neurogen Corporation 6-arylpyridines substituees en position 3
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
WO2004110996A1 (fr) * 2003-06-19 2004-12-23 Pfizer Products Inc. Antagoniste de nk1
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
FR2876692B1 (fr) * 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
JP4058106B2 (ja) 2005-02-18 2008-03-05 アストラゼネカ アクチボラグ 抗菌性のピペリジン誘導体
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
WO2007051062A2 (fr) * 2005-10-28 2007-05-03 Chemocentryx, Inc. Dihydropyridines substituees et leurs methodes d'utilisation
ES2597843T3 (es) 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
WO2008022060A2 (fr) 2006-08-14 2008-02-21 Novartis Ag composés organiques et leurs utilisations
WO2008053270A2 (fr) 2006-10-31 2008-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'un antagoniste du récepteur egfr pour le traitement de la glomérulonéphrite
BRPI0812997A2 (pt) 2007-06-29 2014-12-23 Torrent Pharmaceuticals Ltd Novas piperidonas substituídas como indutores de hsp
EP2331525A4 (fr) 2008-08-11 2013-01-02 Harvard College Analogues d'halofuginone pour l'inhibition d'arnt synthétases et leurs utilisations
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
CA2742802C (fr) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Procedes et compositions pour le traitement de troubles associes au complement
EP3508477B1 (fr) 2008-12-22 2021-11-10 ChemoCentryx, Inc. Antagonistes du c5ar
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2011035143A2 (fr) * 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Procédés et compositions pour inhiber des maladies et des états à médiation par rho
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
CA2877526A1 (fr) 2012-06-20 2013-12-27 Novartis Ag Modulateur de la voie d'activation du complement et ses utilisations
MX368492B (es) 2014-09-29 2019-10-04 Chemocentryx Inc Procesos e compuestos intermedios en la preparacion de antagonistas de c5ar.
JP7339733B2 (ja) 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法

Also Published As

Publication number Publication date
EA201101009A1 (ru) 2012-01-30
AU2009330194B2 (en) 2015-07-09
EP4015504A1 (fr) 2022-06-22
AR077162A1 (es) 2011-08-10
NO2022018I1 (no) 2022-05-31
SG172338A1 (en) 2011-07-28
PL2381778T3 (pl) 2017-01-31
CN102264227A (zh) 2011-11-30
US20170065604A1 (en) 2017-03-09
US20100160320A1 (en) 2010-06-24
NZ594140A (en) 2013-09-27
LT3508477T (lt) 2022-02-10
US20130317028A1 (en) 2013-11-28
NL301166I2 (nl) 2022-07-06
BRPI0923384B1 (pt) 2021-07-27
SMT202200074T1 (it) 2022-03-21
EP3508477A1 (fr) 2019-07-10
HUE030630T2 (en) 2017-05-29
PT3078658T (pt) 2019-07-16
WO2010075257A1 (fr) 2010-07-01
HRP20161010T1 (hr) 2016-10-07
US20190060321A1 (en) 2019-02-28
EP2381778B1 (fr) 2016-06-08
UA112514C2 (uk) 2016-09-26
EP3078658A1 (fr) 2016-10-12
CA2965223A1 (fr) 2010-07-01
EA020874B1 (ru) 2015-02-27
KR20110100661A (ko) 2011-09-14
IL213676A (en) 2015-03-31
KR101680818B1 (ko) 2016-11-29
TWI465434B (zh) 2014-12-21
JP5819730B2 (ja) 2015-11-24
CN102264227B (zh) 2014-07-23
RS54998B1 (sr) 2016-11-30
LTPA2022006I1 (fr) 2022-04-25
PT2381778T (pt) 2016-09-19
SI2381778T1 (sl) 2016-10-28
HK1164639A1 (en) 2012-09-28
CA2747522C (fr) 2017-05-30
EP2381778A1 (fr) 2011-11-02
CA2747522A1 (fr) 2010-07-01
AU2009330194A1 (en) 2011-07-14
FR22C1020I2 (fr) 2023-05-05
US20100311753A1 (en) 2010-12-09
US10660897B2 (en) 2020-05-26
CO6400172A2 (es) 2012-03-15
JO3346B1 (ar) 2019-03-13
CY1125130T1 (el) 2022-07-22
EP2381778A4 (fr) 2012-09-05
EP3078658B1 (fr) 2019-04-10
ES2577548T3 (es) 2016-07-15
BRPI0923384A2 (pt) 2016-06-07
US8906938B2 (en) 2014-12-09
ZA201104588B (en) 2013-11-27
ES2734746T3 (es) 2019-12-11
FR22C1020I1 (fr) 2022-07-15
US8445515B2 (en) 2013-05-21
MX2011006550A (es) 2011-07-20
DK2381778T3 (en) 2016-09-12
EP3508477B1 (fr) 2021-11-10
HUS2200025I1 (hu) 2022-06-28
IL213676A0 (en) 2011-07-31
US20150141425A1 (en) 2015-05-21
JP2012513402A (ja) 2012-06-14
TW201028380A (en) 2010-08-01
CA2965223C (fr) 2019-09-24
DK3078658T3 (da) 2019-07-15

Similar Documents

Publication Publication Date Title
MA32975B1 (fr) Antagonistes de c5ar
CY1112969T1 (el) Ανταγωνιστες πιριδυλ πιπεριδινης του υποδοχεα ορεξινης
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
ATE469895T1 (de) Cgrp-rezeptorantagonisten
DK2049529T3 (da) Substituerede diazepan-orexin-receptor- antagonister
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
CY1113798T1 (el) Υποκατεστημενες ενωσεις διαζεπανης ως ανταγωνιστες υποδοχεα ορεξινης
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
CY1111169T1 (el) Βενζοϊμιδαζολ-2-υλ πυριμιδινες και πυραζινες ως τροποποιητες του υποδοχεα ισταμινης h4
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
MA32568B1 (fr) Formulations pharmaceutiques contenant des ligands de recepteur de dopamine
MY145349A (en) Benzofuro- and benzothienopyrimidine modulators of the histamine h4 receptor
HK1124767A1 (en) Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
EA201171063A1 (ru) Фармацевтические составы олмесартана
EA201190208A1 (ru) Соединения для лечения метаболических расстройств
MX364912B (es) Antagonistas / agonistas inversos del receptor canabinoide.
WO2007115192A3 (fr) Antagonistes du récepteur p2x7 pour traiter des troubles affectifs
WO2010019565A3 (fr) Anticorps anti-ephrine b2 et leur utilisation dans le traitement de maladies